US health regulators clear a digital therapy for lazy eye, bypassing drug trials

US health regulators have created a new, easier path for digital treatments for amblyopia, also known as "lazy eye." This means software developers can now get their digital therapies approved faster, without needing to run expensive drug-style clinical trials.

For decades, medical treatments meant pills or surgery, and getting them approved by regulators was a long, expensive process. This decision means that for certain conditions, software can now be considered a medical device, not a drug. It opens a new, faster regulatory path for digital health companies, allowing them to bring products to market that might otherwise have been too costly or slow to develop.